{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:08:40Z","timestamp":1788930520241,"version":"build-2803163510"},"reference-count":89,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Brain tumors are the most common solid malignancies in children and the leading cause of cancer-related mortality in this age group. Cancer immunotherapy has shown a lot of promise in the treatment of both adult and pediatric cancers. In this review, we summarize the use of immunotherapies in the treatment of pediatric brain tumors with special emphasis on CAR T cells, Immune checkpoint inhibitors and oncolytic viral therapy.<\/jats:p>","DOI":"10.3390\/curroncol33090522","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:19:26Z","timestamp":1788232766000},"page":"522","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cellular and Immunotherapy for Pediatric Brain Tumors: A Primer"],"prefix":"10.3390","volume":"33","author":[{"given":"Irem","family":"Yenidogan","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirav","family":"Thacker","sequence":"additional","affiliation":[{"name":"Hematology-Oncology, Children\u2019s Hospital of Eastern Ontario, Ottawa, ON K1H 8L1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirban","family":"Das","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2015-0615","authenticated-orcid":false,"given":"Magimairajan Issai","family":"Vanan","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Cancer Care Manitoba, Winnipeg, MN R3E 0V9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.it.2019.05.009","article-title":"Towards Immunotherapy for Pediatric Brain tumors","volume":"40","author":"Wang","year":"2019","journal-title":"Trends Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2017.72.8089","article-title":"Immunotherapy for Brain tumors","volume":"35","author":"Sampson","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s43018-021-00319-0","article-title":"The current landscape of immunotherapy for pediatric brain tumors","volume":"3","author":"Hwang","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/archdischild-2023-326081","article-title":"What are CAR T-cells?","volume":"109","author":"Syrimi","year":"2024","journal-title":"Arch. Dis. Child. Educ. Pract. Ed."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Patterson, J.D., Henson, J.C., Breese, R.O., Bielamowicz, K.J., and Rodriguez, A. (2020). CAR T Cell therapy for pediatric brain tumors. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01582"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.trecan.2023.07.007","article-title":"CAR-T cell therapies for diffuse midline glioma","volume":"9","author":"Thomas","year":"2023","journal-title":"Trends Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","article-title":"Forks in the road for CAR T and CAR NK cell cancer therapies","volume":"24","author":"Dagher","year":"2023","journal-title":"Nat. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: Current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a Pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/neuonc\/noaf064","article-title":"Locoregional infusion of EGFR806-CAR T cells for recurrent or refractory pediatric CNS tumors: Results of the completed BrainChild02 phase 1 clinical trial","volume":"27","author":"Gust","year":"2025","journal-title":"Neuro-Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1083\/jcb.102.3.688","article-title":"Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins","volume":"102","author":"Cheresh","year":"1986","journal-title":"J. Cell Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: An interim analysis","volume":"27","author":"Vitanza","year":"2021","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Wang, L., Oill, A.T., Blanchar, M., Wu, M., Hibbard, J., Sepulveda, S., Peter, L., Kilpatrick, J., Munoz, M., and Stiller, T. (2023). Expansion of endogenous T Cells in CSF of pediatric CNS tumor patients undergoing locoregional delivery of IL13R\u03b12-targeting CAR T cells: An interim analysis. Res. Sq., Preprint.","DOI":"10.21203\/rs.3.rs-3454977\/v1"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e004450","DOI":"10.1136\/jitc-2021-004450","article-title":"Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors","volume":"10","author":"Foster","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/neuonc\/nox116","article-title":"CD70, a novel target of CAR T-cell therapy for gliomas","volume":"20","author":"Jin","year":"2018","journal-title":"Neuro Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in Oncology: The new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/imr.12773","article-title":"CAR T cells for brain tumors: Lessons learned and road ahead","volume":"290","author":"Akhavan","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s10555-024-10208-4","article-title":"CAR T cell therapy for pediatric central nervous system tumors: A review of the literature and current North American Trials","volume":"43","author":"Ronsley","year":"2024","journal-title":"Cancer Metastatic Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-025-01227-5","article-title":"The promise of Immunotherapy for central nervous system tumors","volume":"26","author":"Mahdi","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy-assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11060-025-05251-2","article-title":"Neurotoxicity in central nervous system tumors treated with CAR T cell therapy: A review","volume":"176","author":"Mahdi","year":"2026","journal-title":"J. Neuro-Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","article-title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): Interim analysis of an open-label, single-arm, phase 1\u20132 trial","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature25480","article-title":"The landscape of genomic alterations across childhood cancers","volume":"555","author":"Worst","year":"2018","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","article-title":"Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme resulting from Germline Biallelic Mismatch Repair Deficiency","volume":"34","author":"Bouffet","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1158\/1078-0432.CCR-23-0411","article-title":"Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency","volume":"29","author":"Das","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1158\/2159-8290.CD-20-1050","article-title":"Mutations in the RAS\/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition","volume":"11","author":"Campbell","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.cell.2017.09.048","article-title":"Comprehensive Analysis of Hypermutation in Human Cancer","volume":"171","author":"Campbell","year":"2017","journal-title":"Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41591-021-01581-6","article-title":"Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency","volume":"28","author":"Das","year":"2022","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","article-title":"Mechanisms and therapeutic implications of hypermutation in gliomas","volume":"580","author":"Touat","year":"2020","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41588-025-02420-x","article-title":"Mutation patterns drive mismatch repair-deficient glioma evolution","volume":"58","author":"Fernandez","year":"2026","journal-title":"Nat. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"iii407","DOI":"10.1093\/neuonc\/noaa222.560","article-title":"MBRS-54. Poor survival in replication repair deficient hypermutant medulloblastoma and CNS embryonal tumors: A report from the international RRD consortium","volume":"22","author":"Das","year":"2020","journal-title":"Neuro Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e12862","DOI":"10.1111\/nan.12862","article-title":"Recurrent posterior fossa group A (PFA) ependymoma in a young child with constitutional mismatch repair deficiency (CMMRD)","volume":"49","author":"Briggs","year":"2023","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.ccell.2023.09.001","article-title":"TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory","volume":"41","author":"Labiano","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7769","DOI":"10.1038\/s41467-024-52096-w","article-title":"Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function","volume":"15","author":"Andrade","year":"2024","journal-title":"Nat. Comm."},{"key":"ref_42","first-page":"vdaf099","article-title":"Dual targeting of CD155\/TIGIT and PD-L1\/PD-1 immune checkpoints potentiate NK cell-mediated cytotoxicity in medulloblastoma","volume":"7","author":"Monnikhof","year":"2025","journal-title":"Neurooncol Adv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1038\/s41467-024-49595-1","article-title":"Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment","volume":"15","author":"Levine","year":"2024","journal-title":"Nat. Comm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology: A report of the RANO working group","volume":"16","author":"Okada","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults","volume":"41","author":"Wen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.3174\/ajnr.A8396","article-title":"A Neuroradiologist\u2019s Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults","volume":"45","author":"Ellingson","year":"2024","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11060-026-05491-w","article-title":"Immune Checkpoint Inhibitors in pediatric central nervous system tumors: Biology, clinical experience, and translational pathways to precision immunotherapy","volume":"177","author":"Yenidogan","year":"2026","journal-title":"J. Neurooncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/2159-8290.CD-23-0559","article-title":"Combined Immunotherapy improves outcome for replication-repair-deficient (RRD) High-Grade glioma failing anti-PD-1 monotherapy: A report from the international RRD consortium","volume":"14","author":"Das","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e7154","DOI":"10.1002\/cam4.7154","article-title":"Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center","volume":"13","author":"Gikandi","year":"2024","journal-title":"Cancer Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11060-016-2190-1","article-title":"Pembrolizumab: First experience with recurrent primary central nervous system (CNS) tumors","volume":"129","author":"Blumenthal","year":"2016","journal-title":"J. Neuro-Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1097\/MPH.0000000000001339","article-title":"Nivolumab in the treatment of recurrent or refractory pediatric brain tumors: A single institutional experience","volume":"41","author":"Gorsi","year":"2019","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11060-020-03578-6","article-title":"Immune checkpoint inhibition for pediatric patients with recurrent\/refractory CNS tumors: A single institution experience","volume":"149","author":"Cacciotti","year":"2020","journal-title":"J. Neuro-Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s11060-018-2991-5","article-title":"Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: A single institution experience","volume":"140","author":"Kline","year":"2018","journal-title":"J. Neuro-Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1634\/theoncologist.2018-0163","article-title":"Durable response to nivolumab in a pediatric patient with refractory Glioblastoma and constitutional biallelic mismatch repair deficiency","volume":"23","author":"AlHarbi","year":"2018","journal-title":"Oncologist"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e2100286","DOI":"10.1200\/PO.21.00286","article-title":"Immune checkpoint inhibition as single therapy for synchronous cancers exhibiting hypermutation: An IRRDC study","volume":"6","author":"Henderson","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Jhawar, S.R., Thandoni, A., Bommareddy, P.K., Hassan, S., Kohlhapp, F.J., Goyal, S., Schenkel, J.M., Silk, A.W., and Zloza, A. (2017). Oncolytic viruses- natural and genetically engineered cancer immunotherapies. Front. Oncol., 7.","DOI":"10.3389\/fonc.2017.00202"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1093\/emboj\/17.12.3351","article-title":"The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus","volume":"17","author":"Strong","year":"1998","journal-title":"EMBO J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1016\/j.neuron.2022.09.002","article-title":"Myeloid cell interferon secretion restricts Zika flavivirus infection of developing and malignant human neural progenitor cells","volume":"110","author":"Bulstrode","year":"2022","journal-title":"Neuron"},{"key":"ref_59","first-page":"120","article-title":"A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency","volume":"7","author":"Suzuki","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.immuni.2011.05.006","article-title":"Toll-like receptors and their crosstalk with other innate receptors in infection and immunity","volume":"34","author":"Kawai","year":"2011","journal-title":"Immunity"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.4049\/jimmunol.171.8.4320","article-title":"Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses","volume":"171","author":"Betts","year":"2003","journal-title":"J. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1158\/1078-0432.CCR-20-3313","article-title":"Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT\/RT and CNS-PNET","volume":"27","author":"Labiano","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e1442169","DOI":"10.1080\/2162402X.2018.1442169","article-title":"Heating it up: Oncolytic viruses make tumors \u201chot\u201d and suitable for checkpoint blockade immunotherapies","volume":"7","author":"Gujar","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e002644","DOI":"10.1136\/jitc-2021-002644","article-title":"CD137 and PD-L1 targeting immuno-virotherapy induces a potent and durable antitumor immune response in glioblastoma models","volume":"9","author":"Puigdelloses","year":"2021","journal-title":"J. ImmunoTher. Cancer"},{"key":"ref_66","first-page":"108193","article-title":"Clinical advances in oncolytic virotherapy for pediatric brain tumors","volume":"23","author":"Kang","year":"2022","journal-title":"Pharm. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1172\/JCI116527","article-title":"Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models","volume":"91","author":"Whitley","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm0995-938","article-title":"Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas","volume":"1","author":"Mineta","year":"1995","journal-title":"Nat. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1073\/pnas.101136398","article-title":"Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing","volume":"98","author":"Todo","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1128\/AAC.33.8.1395","article-title":"Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir","volume":"33","author":"Coen","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/humc.2016.031","article-title":"Design of Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent\/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma","volume":"27","author":"Patel","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41417-019-0091-0","article-title":"Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice","volume":"27","author":"Bernstock","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11060-009-9926-0","article-title":"Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111","volume":"95","author":"Friedman","year":"2009","journal-title":"J. Neurooncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/neuonc\/nov123","article-title":"Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses","volume":"18","author":"Friedman","year":"2016","journal-title":"Neuro Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"13930","DOI":"10.1038\/s41598-018-32353-x","article-title":"Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression","volume":"8","author":"Friedman","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.omto.2017.05.005","article-title":"Oncolytic Herpes Virus rRp450 Shows Efficacy in Orthotopic Xenograft Group 3\/4 Medulloblastomas and Atypical Teratoid\/Rhabdoid Tumors","volume":"6","author":"Studebaker","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","article-title":"Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway","volume":"95","author":"Fueyo","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41467-019-10043-0","article-title":"The oncolytic virus Delta-24- RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models","volume":"10","author":"Marigil","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40478-019-0714-6","article-title":"Delta-24-RGD combined with radiotherapy exerts a potent anti-tumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models","volume":"7","author":"Marigil","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"14368","DOI":"10.1038\/s41598-019-51014-1","article-title":"The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models","volume":"9","author":"Marradan","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-20-1499","article-title":"Mesenchymal stem cells successfully deliver oncolytic virotherapy to diffuse intrinsic pontine glioma","volume":"27","author":"Chastkofsky","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/jnen\/nly045","article-title":"Poliovirus receptor (CD155) expression in pediatric brain tumors mediates oncolysis of medulloblastoma and pleomorphic xanthoastrocytoma","volume":"77","author":"Thompson","year":"2018","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1126\/science.282.5392.1332","article-title":"Reovirus therapy of tumors with activated ras pathway","volume":"282","author":"Coffey","year":"1998","journal-title":"Science"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/neuonc\/nor231","article-title":"Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid disseminated medulloblastoma","volume":"14","author":"Studebaker","year":"2012","journal-title":"Neuro Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/neuonc\/nov058","article-title":"Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors","volume":"17","author":"Studebaker","year":"2015","journal-title":"Neuro Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","article-title":"GYG. Oncolytic HSV-1 G207 immunovirotherapy for pediatric high- grade gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX- 2401 virus for pediatric diffuse intrinsic pontine glioma","volume":"386","author":"Labiano","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00381-025-06981-4","article-title":"The effect of oncolytic virotherapy on pediatric brain tumor- a systematic review","volume":"41","author":"Velammal","year":"2025","journal-title":"Childs Nerv. Syst."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S2352-4642(23)00031-7","article-title":"Recombinant polio\u2013rhinovirus immunotherapy for recurrent pediatric high-grade glioma: A phase 1b trial","volume":"7","author":"Thompson","year":"2023","journal-title":"Lancet Child Adolesc. Health"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/522\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:21:44Z","timestamp":1788927704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":89,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["curroncol33090522"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33090522","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}